ArticleIranian journal of child neurology2026
Comparing Neurodevelopmental Outcome among Neonates with Jaundice Due to ABO and Rh Incompatibility.
Article in Iranian journal of child neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Evaluating risk factors is essential in the context of hyperbilirubinemia and its clinical outcomes, particularly when attributed to its primary causes: maternal-fetal ABO and Rh incompatibility. This study aims to determine the prevalence rate of predisposing factors and complications of hyperbilirubinemia in newborns with ABO blood group incompatibility, compared to those with Rh incompatibility. Materials & Methods: This is a descriptive-analytical study. The newborns with jaundice who were referred to Ghaem Teaching Hospital affiliated to the Mashhad University of Medical Sciences, Mashhad, Iran, from 2017 to 2019, divided into two groups of ABO incompatibility (n = 83) and Rh incompatibility (n = 81). The neurodevelopmental assessment was performed by Denver Developmental Screening Test II (DDST-II). Following that, a comparison was made between these two groups. Results: The mean age of the ABO incompatibility group was 5.84 days and the Rh incompatibility group was 4.91 days at admission time. The mean values of bilirubin level obtained at 28.26 ± 5.9 and 30.17 ± 8.19 in newborns with ABO and Rh incompatibility (P = 0.089). No significant difference was observed between the two groups regarding age, Apgar score, bilirubin level (P > 0.05), delivery type (χ Conclusion: Despite similar bilirubin levels and treatment approaches, neonates with Rh incompatibility experienced significantly higher rates of developmental delay compared to those with ABO incompatibility. By age three, moderate to severe delays were more frequent in the Rh group, underscoring the greater neurodevelopmental risk associated with Rh-mediated hemolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.